Episode 1: Exploring Psychedelics in Psychiatric Treatment with Professor Roger McIntyre

In this inaugural episode of Psychopharm Today, host Dr. Josh Rosenblat sits down with renowned psychiatrist and researcher, Professor Roger McIntyre, to discuss the growing field of psychedelics research and its potential impact on psychiatric treatment.

Dr. Rosenblat is psychiatrist, associate professor, and clinician researcher at the University of Toronto.  His research focus is clinical trials of novel psychopharmacological interventions for mood disorders and symptoms that do not respond fully to available treatments.  His current research includes trials involving Ketamine and Psilocybin. 

Dr. McIntyre  is a psychiatrist and Fellow of The Royal College of Physicians of Canada.  He is currently a Professor of Psychiatry and Pharmacology at the University of Toronto.  Since 2014, he has been repeatedly named by Clarivate Analytics as one of “The World’s Most Influential Scientific Minds,” and just last year, he was awarded the Colvin Prize for Outstanding Achievement in Mood Disorders Research from the Brain and Behavior Foundation.  Dr. McIntyre's research has aimed to characterize the phenomenology, neurobiology, and novel therapeutics of mood disorders.  He has been especially interested in identifying innovative, rapid acting psychotropic treatments for mood disorders. 

Dr. McIntyre has also been extensively involved in medical education and has received numerous teaching awards, and has contributed significantly to clinical practice guidelines.  He is the lead author of the International Expert Opinion on the Available Evidence and Implementation of Ketamine and Esketamine in mood disorders.

----more----

Psychopharm Today is brought to you by the ASCP Technology Committee

Produced by Zhi-De Deng, Ph.D., National Institute of Mental Health
Introduction by Jessica Gannon, M.D., University of Pittsburgh School of Medicine
Hosted by Joshua Rosenblat, M.D., University of Toronto

Other Committee Members:

• Rajiv Radhakrishnan, M.D., Yale School of Medicine, Chair
• Crystal Cooper, Ph.D., The University of Texas Southwestern Medical Center, Department of Psychiatry, Co-Chair
• Stefano Comai, Ph.D., Pharm.D., University of Padua
• Michael Henry, M.D., Massachusetts General Hospital
• Bashkim Kadriu, M.D., FAPA, Jazz Pharmaceuticals, Inc.
• Matthew Macaluso, D.O., The University of Alabama At Birmingham
• Nivedita Nadkarni, M.D., Essentia health
• Andrew Olagunju, M.D., M.Sc., Ph.D., McMaster University
• Daniel Umbricht, M.D., Xperimed GmbH

Join us as we explore the latest in psychopharmacology, featuring expert insights and innovative discussions from leaders in the field.